1. Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?
   Rashmi R. Shah, 2017, Drug Safety CrossRef
2. Axitinib-induced reversible posterior leukoencephalopathy syndrome in a patient with metastatic renal cell carcinoma
   Kogenta Nakamura et al, 2017, International Cancer Conference Journal CrossRef
3. The clinical characteristics of posterior reversible encephalopathy syndrome in patients with chronic renal failure
   Hongtao Hu et al, 2017, Experimental and Therapeutic Medicine CrossRef
4. Reversible Posterior Leukoencephalopathy Syndrome During Regorafenib Treatment: A Case Report and Literature Review of Reversible Posterior Leukoencephalopathy Syndrome Associated With Multikinase Inhibitors
   Zaw W. Myint et al, 2014, Clinical Colorectal Cancer CrossRef
5. Posterior Reversible Encephalopathy Syndrome as an Adverse Effect of Lenvatinib in a Patient with Papillary Thyroid Carcinoma: A Case Report
   Daisy Carolina Buenaventura et al, 2023, International Journal of Endocrinology and Metabolism CrossRef
6. Recombinant human endostatin as a potential anti-angiogenic agent: therapeutic perspective and current status
   J. Anakha et al, 2023, Medical Oncology CrossRef
7. Reversible Posterior Leukoencephalopathy Syndrome Developing After Restart of Sunitinib Therapy for Metastatic Renal Cell Carcinoma
   Shinji Fukui et al, 2016, Case Reports in Medicine CrossRef
8. Implementing Reverse Phase Protein Array Profiling as a Sensitive Method for the Early Pre‐Clinical Detection of Off‐Target Toxicities Associated with Sunitinib Malate
   Alice C. O'Farrell et al, 2019, PROTEOMICS – Clinical Applications CrossRef
9. Rare anti-VEGFR therapy-induced toxicity and long-term response to immunotherapy in a rare non-clear cell renal cell carcinoma patient
   Fabio Catalano et al, 2022, Anti-Cancer Drugs CrossRef
10. Posterior reversible encephalopathy syndrome due to targeted agents: vemurafinib among suspects!
    Arushi Khurana et al, 2015, Journal of Oncology Pharmacy Practice CrossRef
11. Insight in taste alterations during treatment with protein kinase inhibitors
    A. van der Werf et al, 2017, European Journal of Cancer CrossRef
12. Reversible Posterior Encephalopathy Syndrome Secondary to Sunitinib
    Ricardo Costa et al, 2014, Case Reports in Oncological Medicine CrossRef
13. Posterior Reversible Encephalopathy Syndrome after Lenvatinib Therapy in a Patient with Olfactory Neuroblastoma
    Yu-Ju Tseng et al, 2022, Brain Sciences CrossRef
14. Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients?
    Giovanni Brandi et al, 2013, Liver International CrossRef
15. Posterior Reversible Leukoencephalopathy Syndrome Associated with Pazopanib
    Robert Foerster et al, 2013, Case Reports in Oncology CrossRef
16. Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review
    Young Kwang Chae et al, 2018, Oncotarget CrossRef
17. Clinical pharmacology of anti-angiogenic drugs in oncology
    P. Gougis et al, 2017, Critical Reviews in Oncology/Hematology CrossRef